The signing ceremony of Pamedic Holdings' project was successfully held in Shenzhen.

On November 24th, the signing ceremony of Pamedic Holdings, organized by the host company Pamedic Holdings (Shenzhen) Co., Ltd. and co-organized by C Cheng Holdings Co., Ltd., took place at the Yangtze Hall of Wuzhou Guest House in Shenzhen, Guangdong Province.

Pamedic Holdings (Shenzhen) Co., Ltd. has gathered top talents from both China and the United Kingdom in the field of isotopes, including Fellows of the Royal Society and Fellows of the Royal Academy of Engineering in the UK, former Chief Scientist of the Canadian Nuclear Laboratory, as well as nuclear experts and professors from Tsinghua University and the Chinese Academy of Sciences. This marks a significant milestone for Pamedic Holdings, signaling its commitment to bringing new breakthroughs and advancements to the medical and health sector. The company is dedicated to building an internationally integrated nuclear medicine enterprise with a complete industry chain spanning research and development, production, and commercialization of isotopes, ligands, and pharmaceuticals.

▲From left to right: Ronald Liang, Founder and Chairmanof C Cheng Holdings、Mark Wong, Managing Director of MWA in Hong Kong、

Andrew Carlick, Founder and Director of PMHL in the UK 、Ivan Fu,Executive Director and President of C Cheng Holdings、

and Leo Dang, Executive Director of C Cheng Holdings and President of Panmediso Holdings ,during the photo session.

The medical isotope research, development, production, and sales enterprise, Pamedic Holdings, jointly initiated by C Cheng Holdings Limited, MWA.T Industrial Advisory Company, and the PM UK team, has officially signed the agreement. By leveraging the combined strengths of resources from various parties, the company aims to provide GMP-grade production of novel isotopes and global supply, meeting the ever-growing demands in the medical field.

▲From left to right: Qiu Chunhua, Senior Director of Market and Strategy for Fluor in the Greater China Region, 

and Leo Dang, Executive Director of C Cheng Holdings and President of Pamedic Holdings, during the photo session.

Simultaneously, Pamedic Holdings and the core project supplier, Fluor Corporation from the United States, have officially signed a strategic cooperation agreement. Both parties will leverage their respective strengths to jointly advance the establishment of the project's production base.

As a leading enterprise in the field of nuclear medicine, Pamedic will fill the void in China's isotope supply sector, integrate the entire isotope industry chain, establish a nuclear medicine hub unique to China, and provide a forward-looking expert team to lead the way for precision medicine, technological innovation, and the promotion of a healthy lifestyle in the national healthcare industry. Pamedic aims to contribute to domestic nuclear medicine research innovation, results transformation, and sustained development by offering an internationally advanced talent cultivation mechanism and platform.